1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as CBL' receptor modulator

Details for Australian Patent Application No. 2007329807 (hide)

Owner Eli Lilly and Company

Inventors Schaus, John Mehnert; Heath, Perry Clark

Agent Spruson & Ferguson

Pub. Number AU-A-2007329807

PCT Pub. Number WO2008/070305

Priority 60/862,540 23.10.06 US

Filing date 22 October 2007

Wipo publication date 12 June 2008

International Classifications

A61K 31/4025 (2006.01) - not condensed and containing further heterocyclic rings, e.g. cromakalim

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

C07D 207/38 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

23 April 2009 PCT application entered the National Phase

  PCT publication WO2008/070305 Priority application(s): WO2008/070305

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007329808-1,5-diphenyl-3-benzylamino-1,5-dihydro pyrrolidin-2-one as CB1 receptor modulators

2007329793-Improved linkers for anchoring targeting ligands